Global Nicotinamide Mononucleotide (NMN) Market Strategic Research Report

Scope of the Report

The global Nicotinamide Mononucleotide (NMN) market size is predicted to grow from US$ 196 million in 2025 to US$ 388 million in 2032; it is expected to grow at a CAGR of 8.9% from 2026 to 2032.

In 2025, global sales volume of Nicotinamide Mononucleotide (NMN) reached 397.8 metric tons, with an average price of $478 per kilogram.

Nicotinamide mononucleotide (NMN) is an intermediate of NAD+ biosynthesis produced from nicotinamide through nicotinamide phosphoribosyltransferase (NAMPT) and also referred to as NMN or nicotinamide ribotide. In recent studies of NMN applications to prevention and diagnosis of age-dependent diseases such as diabetes, neurodegenerative disorder, cardiac disease etc., it has become one of hottest biomarkers on discussion for anti-aging, lately.

NMN is a precursor of nicotinamide adenine dinucleotide (NAD+), which plays a vital role in cell metabolism and energy production. As we age, the level of NAD+ in the human body gradually decreases, resulting in weakened cell metabolism, which in turn triggers a series of aging-related diseases. Therefore, increasing the level of NAD+ in the body by supplementing NMN has become a new way to fight aging and maintain good health.

With the general improvement of global health awareness and continuous breakthroughs in scientific research and technology, the growth momentum of the NMN market will continue to increase. In the future, the NMN market will achieve a deeper cross-border integration with other health industries such as biotechnology, precision medicine, and nutritional supplements, giving rise to a series of innovative products and service models to meet consumers' more personalized and precise health needs.

At present, nicotinamide mononucleotide (NMN) is still in the development stage. There are not many manufacturers in the global market, and consumers have weak awareness of its use, especially in developing countries. The demand is lower than that in developed countries around the world, but the demand in developing countries is growing rapidly. Leading giants have proposed expansion plans and increased production bases.

Nicotinamide mononucleotide (NMN) core manufacturers include GeneHarbor, Mirailab Bioscience, Maac10 Formulas, Herbalmax and Genex Formula. China is the largest production area, accounting for about 84% of the global market share, followed by North America and Japan. The downstream applications of nicotinamide mononucleotide include health products, cosmetics, etc. Globally, health products are the largest application market, and raw materials for health products account for 82% of the total sales of nicotinamide mononucleotide in 2025.

This report presents a comprehensive overview of the global Nicotinamide Mononucleotide (NMN) market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Content ≥98%
• Content ＜98%

Segment by Production Process

• Enzymatic Catalysis
• Microbial Fermentation
• Chemical Synthesis
• Other

Segment by Grade

• Food Grade
• Cosmetic Grade
• Pharmaceutical Grade

Segment by Application

• Health Care Products
• Cosmetics
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Nicotinamide Mononucleotide (NMN) market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Health Care Products, Cosmetics, Others evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact